Pharmaceutical

Propanc Biopharma shared a key update on its Patent Cooperation Treaty patent application within its intellectual property.

Propanc Biopharma (OTCQB:PPCB) shared a key update on its Patent Cooperation Treaty patent application within its intellectual property.
As quoted in the press release:

The Company received a Written Opinion from an International Search Authority regarding the novelty, inventive step and industrial applicability of the invention claimed in the recent PCT application, filed in April, 2017. The PCT application titled “Composition of Proenzymes for Cancer Treatment” is directed to a composition comprising trypsinogen and chymotrypsinogen, targeting specific weight ratios and certain dosage levels for the Company’s lead product, PRP. The majority of claims were considered novel and a number of claims considered inventive, as determined by the Authorized Officer from the Australian Patent Office. Furthermore, it appears that the experimental data included in the application and the way it is presented adequately supports the pending claims. The PCT assists applicants in seeking patent protection internationally for their inventions and the Written Opinion can guide national patent offices with their patent granting decisions. By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries.
“We continue to make significant progress with our IP portfolio and look forward to entering the national phase where we will seek to obtain jurisdiction in key countries and regions, globally,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “We remain committed to further establishing ourselves as the lead player in a new and exciting field of oncology, using proenzymes as a means to halt progression of cancer from solid tumors. Hence, we continue to work hard along with our partner research organizations and scientific experts to explore new opportunities to expand our portfolio, and to also discover new treatments methods and compounds which even further enhances the effects of PRP.”

Click here to read the full press release.

Source: www.marketwired.com

MARKETS

Markets
TSX19089.00-133.74
TSXV626.34-18.57
DOW31040.64+93.65
S&P 5003819.16-2.39
NASD11166.87-14.67
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1818.66+0.09
Silver20.81-0.01
Copper3.77-0.01
Palladium1964.50+95.50
Platinum918.50+8.50
Oil109.71-2.05
Heating Oil3.96-0.15
Natural Gas6.49-0.08

DOWNLOAD FREE REPORTS

×